Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes  Maxwell O. Adibe,

Slides:



Advertisements
Similar presentations
Volume 15, Issue 8, Pages (December 2012)
Advertisements

Performance Assessment of the Juaboso District Office of the National Health Insurance Authority  Paul Effah, MBA, Kingsley Opoku Appiah, PhD, FCCA, Patience.
Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results  Becky Pennington, MSc,
Volume 15, Issue 1, Pages S20-S28 (January 2012)
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Volume 15, Issue 2, Pages (March 2012)
Volume 15, Issue 6, Pages (September 2012)
Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis  Klára Kruntorádová, MSc, Jiří Klimeš,
Volume 15, Issue 2, Pages (March 2012)
Value in Health Regional Issues
Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico  Kely Rely, Rosa María.
Value in Health Regional Issues
Value in Health Regional Issues
Eric Nsiah-Boateng, MPH, Moses Aikins, PhD 
Value in Health Regional Issues
The Development of the Romanian Scorecard HTA System
Value in Health Regional Issues
Using Dynamic Transmission Modeling to Determine Vaccination Coverage Rate Based on 5-Year Economic Burden of Infectious Disease: An Example of Pneumococcal.
Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary  András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.
Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation.
Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future?  Emmanuel Ankrah Odame, MBCHB, MPH  Value in.
Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost- Effectiveness Affordability Curves in Health Care Decision Making 
Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico  Kely Rely, Rosa María.
The Process of Privatization of Health Care Provision in Poland
Ernest Attuquaye Quaye, BPharm, MPH, Edward O
Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis  Klára Kruntorádová, MSc, Jiří Klimeš,
Value in Health Regional Issues
Radiology Services Costs and Utilization Patterns Estimates in Southeastern Europe—A Retrospective Analysis from Serbia  Mihajlo Jakovljević, MD, PhD,
Rutger Daems, PhD, Edith Maes, DBA, Christoph Glaetzer, Dipl, Kfm 
Cost-Effectiveness Analysis of a Screening Program for Breast Cancer in Vietnam  Lan Hoang Nguyen, Wongsa Laohasiriwong, John Frederick Stewart, Pamela.
Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,
Value in Health Regional Issues
Value in Health Regional Issues
Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore  Vivianne Shih, PharmD, BCOP, BCPS, Alexandre Chan, PharmD,
Assessment of Adverse Events and Quality of Life of Cancer Patients in a Secondary Level Care, Rural Hospital in South India  S.K.R. Sowmya, PharmD, Dixon.
Cost-Effectiveness of Radiofrequency Ablation for Supraventricular Tachycardia in Guatemala  Benjamin Cruz Rodriguez, MD, Sergio Leal, MD, Gonzalo Calvimontes,
Assessment of Effect of Diabetes on Health-Related Quality of Life in Patients with Coronary Artery Disease Using the EQ-5D Questionnaire  Bhavik Shah,
Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation.
Jinhyun Kim, PhD, Eunhee Lee, PhD, Sungjae Kim, PhD, Tae Jin Lee, PhD 
Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD 
Omneya Mohamed, PhD, David H. Kreling, PhD 
Analysis of Excess Direct Medical Costs of Vision Impairment in Taiwan
Value in Health Regional Issues
A Framework for Applying Health Technology Assessment in Cyprus: Thoughts, Success Stories, and Recommendations  Panagiotis Petrou, MBA, PhD, PhDc, Michalis.
Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary  András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.
Transforming Public Servants’ Health Care Organization in Greece through the Implementation of an Electronic Referral Project  Kyriakos Souliotis, PhD,
Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective  Bruno Salgado Riveros,
Generalized Cost-Effectiveness Analysis of Pharmaceutical Interventions for Primary Prevention of Cardiovascular Disease in Thailand  Panrasri Khonputsa,
Reconciling Cancer Care Costs Reported by Different Government Agencies in Taiwan: Why Costing Approach Matters?  Chun-Ru Chien, MD, PhD, Ya-Chen Tina.
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Incidence of Intravenous Medication Errors in a Chinese Hospital
The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System  Juan Guillermo Ariza, MD, MSc, Per-Olof Thuresson,
Use of the EQ-5D Instrument and Value Scale in Comparing Health States of Patients in Four Health Care Programs among Health Care Providers  Valentina.
Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD 
Value in Health Regional Issues
Value in Health Regional Issues
Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea  Ji Haeng Heo, MS, Karen L.
Dossier System as a Practical Tool for Compiling Reimbursement Lists
Concept of Combining Cost-Effectiveness Analysis and Budget Impact Analysis in Health Care Decision-Making  Roza Ismailovna Yagudina, PhD, Andrey Urievich.
Value in Health Regional Issues
Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico 
Performance Assessment of the Juaboso District Office of the National Health Insurance Authority  Paul Effah, MBA, Kingsley Opoku Appiah, PhD, FCCA, Patience.
The Drug Reimbursement Decision-Making System in Iran
Social Cost of Substance Abuse in Russia
Anut Sakulsupsiri, MSc, Phantipa Sakthong, PhD, Win Winit-Watjana, PhD 
Cost-Utility Analysis of Depot Atypical Antipsychotics for Chronic Schizophrenia in Croatia  Vlado Jukic, MD, PhD, Miro Jakovljevic, MD, PhD, Igor Filipcic,
Victoria I. Ignatyeva, MPH, Johan L
Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational.
Cost-Effectiveness of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov.
Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD 
Presentation transcript:

Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes  Maxwell O. Adibe, BPharm, MPharm, PhD, Cletus N. Aguwa, PharmD, Chinwe V. Ukwe, BPharm, MPharm, PhD  Value in Health Regional Issues  Volume 2, Issue 2, Pages 189-198 (September 2013) DOI: 10.1016/j.vhri.2013.06.009 Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 Cost-effectiveness plane. NGN, Nigerian naira; QALYs, quality-adjusted life-years. Value in Health Regional Issues 2013 2, 189-198DOI: (10.1016/j.vhri.2013.06.009) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 2 Net monetary benefit of PC and UC at different levels of willingness to pay for a QALY. NGN, Nigerian naira; PC, pharmaceutical care; QALY, quality-adjusted life-year; UC, usual care. Value in Health Regional Issues 2013 2, 189-198DOI: (10.1016/j.vhri.2013.06.009) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 3 Univariate sensitivity analysis of cost and utility variables on incremental cost-effectiveness ratio. NGN, Nigerian naira; QALY, quality-adjusted life-year. A = QALY (±10%); B = Adjustment rate (3% and 6%); C = Total intervention-specific cost (±20%); D = Cost of antidiabetes medications (±20%); E = Cost of antihypertensives (±20%); F = Cost of antidiabetes + antihypertensives medications (±20%); G = Total cost of drugs (±20%); H = Hospital care cost (±20%); I = Auxiliary health care cost (±20%). Value in Health Regional Issues 2013 2, 189-198DOI: (10.1016/j.vhri.2013.06.009) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 4 Cost-effectiveness acceptability curves. NGN, Nigerian naira; QALY, quality-adjusted life-year. Value in Health Regional Issues 2013 2, 189-198DOI: (10.1016/j.vhri.2013.06.009) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.